Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-Label, Single-Arm, Multidose Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this phase 2, open-label, single-arm, multidose, multicenter study is to investigate the effects of Orteronel plus Prednisone on the QT/QTc interval in patients with Metastatic Castration-Resistant Prostrate Cancer
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
Pinnacle Oncology
Scottsdale, Arizona, United States
Start Date
May 1, 2012
Primary Completion Date
January 1, 2015
Completion Date
January 1, 2015
Last Updated
June 1, 2016
50
ACTUAL participants
Orteronel+Prednisone
DRUG
Lead Sponsor
Millennium Pharmaceuticals, Inc.
NCT06842498
NCT04550494
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05691465